Immunopathogenesis of Behçet Disease

Author(s): Israel Gañán Nieto*, José Luis Castañer Alabau

Journal Name: Current Rheumatology Reviews

Volume 16 , Issue 1 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Behçet’s Disease (BD, OMIM 109650) is a chronic relapsing inflammatory disease of unknown etiology with unpredictable exacerbations and remissions. First described in 1937 by the Turkish dermatologist HulusiBehçet, as a trisympton complex (oral and genital ulcers and uveitis), it is now recognized as a multisystemic disease. The syndrome can manifest in diverse ways and can involve nearly every organ system. Several studies have implicated T cells and monocytes in the pathogenesis of BD especially when these cells are stimulated by heat shock proteins and streptococcal antigen. This article presents a review of the relevant published literature about the immunopathogenesis of BD.

Result: The authors used MeSH terms “Behçet’s disease” with “pathophysiology,” “pathogenesis,” “genetic”, “epigenetic”, “immunogenetic” or “immune response” to search the PubMed database. All the relevant studies identified were included.

Keywords: Behçet's disease, genetics, epigenetics, immunopathogenesis, etiology, pathophysiology.

[1]
Behçet H. Überrezidivierendeaphthöse, durchein Virus verursachteGeschwüre am Mund, am Auge und an den Genitalien. Dermatol Monatsschr 1937; 105: 1152-7.
[2]
Pay S, Simşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 2007; 27(5): 417-24.
[http://dx.doi.org/10.1007/s00296-006-0281-6] [PMID: 17171346]
[3]
Kulaber A, Tugal-Tutkun I, Yentür SP, et al. Pro-inflammatory cellular immune response in Behçet’s disease. Rheumatol Int 2007; 27(12): 1113-8.
[http://dx.doi.org/10.1007/s00296-007-0367-9] [PMID: 17549482]
[4]
Dalvi SR, Yildirim R, Yazici Y. Behcet’s Syndrome. Drugs 2012; 72(17): 2223-41.
[http://dx.doi.org/10.2165/11641370-000000000-00000] [PMID: 23153327]
[5]
Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev 2010; 9(4): 241-5.
[http://dx.doi.org/10.1016/j.autrev.2009.10.005] [PMID: 19879978]
[6]
Suzuki Kurokawa M, Suzuki N. Behcet’s disease. Clin Exp Med 2004; 4(1): 10-20.
[http://dx.doi.org/10.1007/s10238-004-0033-4] [PMID: 15598081]
[7]
Choukri F, Chakib A, Himmich H, Hüe S, Caillat-Zucman S. HLA-B*51 and B*15 alleles confer predisposition to Behçet’s disease in Moroccan patients. Hum Immunol 2001; 62(2): 180-5.
[http://dx.doi.org/10.1016/S0198-8859(00)00249-4] [PMID: 11182229]
[8]
Horie Y, Meguro A, Ohta T, et al. HLAB51 Carriers are susceptible to ocular symptoms of Behçet’s Disease and the association between the two becomes stronger towards the East along the Silk Road: a literature survey. Ocul Immunol Inflamm 2017; 25(1): 37-40.
[http://dx.doi.org/10.3109/09273948.2015.1136422] [PMID: 26954704]
[9]
Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012; 11(10): 687-98.
[http://dx.doi.org/10.1016/j.autrev.2011.11.026] [PMID: 22197900]
[10]
Ombrello MJ, Kirino Y, de Bakker PI, Gül A, Kastner DL, Remmers EF. Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci USA 2014; 111(24): 8867-72.
[http://dx.doi.org/10.1073/pnas.1406575111] [PMID: 24821759]
[11]
Ortiz-Fernández L, Carmona FD, Montes-Cano MA, et al. Genetic analysis with the immunochip platform in behçet disease. identification of residues associated in the HLA class I region and new susceptibility loci. PLoS One 2016; 11(8)e0161305
[http://dx.doi.org/10.1371/journal.pone.0161305] [PMID: 27548383]
[12]
Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45(2): 202-7.
[http://dx.doi.org/10.1038/ng.2520] [PMID: 23291587]
[13]
Zervoudi E, Saridakis E, Birtley JR, et al. Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. Proc Natl Acad Sci USA 2013; 110(49): 19890-5.
[http://dx.doi.org/10.1073/pnas.1309781110] [PMID: 24248368]
[14]
Wallace GR, Verity DH, Delamaine L, et al. Association with MICA alleles with Behcet’s disease. Immunogenetics 1999; 49: 613-7.
[http://dx.doi.org/10.1007/s002510050656] [PMID: 10369918]
[15]
Nashida T, Hiruyama K, Nakaruma S, et al. Proliferative response of CD8+ (gamma) (delta) T cells recovered from eyes of patients with Behcet’s disease recognize prenyl pyrophosphate antigens. J Neuroimmunol 2002; 130: 46-54.
[http://dx.doi.org/10.1016/S0165-5728(02)00208-4] [PMID: 12225887]
[16]
Verity DH, Wallace GR, Seed PT, et al. Soluble adhesion molecules in Behçet’s disease. Ocul Immunol Inflamm 1998; 6(2): 81-92.
[http://dx.doi.org/10.1076/ocii.6.2.81.4054] [PMID: 9689638 ]
[17]
Krause I, Weinberger A. Behçet’s disease. Curr Opin Rheumatol 2008; 20(1): 82-7.
[http://dx.doi.org/10.1097/BOR.0b013e3282f154d1] [PMID: 18281862 ]
[18]
Erer B, Takeuchi M, Ustek D, et al. Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet’s disease. Genes Immun 2016; 17(7): 396-9.
[http://dx.doi.org/10.1038/gene.2016.36] [PMID: 27708262]
[19]
Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis 2014; 5(3): 112-34.
[http://dx.doi.org/10.1177/2040622314523062] [PMID: 24790727]
[20]
Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001; 19(5)(Suppl. 24): S6-S12.
[PMID: 11760403]
[21]
Takeuchi M, Mizuki N, Meguro A, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet’s disease susceptibility. Nat Genet 2017; 49(3): 438-43.
[http://dx.doi.org/10.1038/ng.3786] [PMID: 28166214]
[22]
Qin X, Xu J, Wu Z, et al. Association study of rs924080 and rs11209032 polymorphisms of IL23R-IL12RB2 in a Northern Chinese Han population with Behcet’s disease. Hum Immunol 2016; 77(12): 1284-90.
[http://dx.doi.org/10.1016/j.humimm.2016.09.006] [PMID: 27660093]
[23]
Chen F, Xu L, Zhao T, Xiao X, Pan Y, Hou S. Genetic variation in the REL gene increases risk of Behçet’s disease in a Chinese Han Population but that of PRKCQ does not. PLoS One 2016; 11(1)e0147350
[http://dx.doi.org/10.1371/journal.pone.0147350] [PMID: 26784953]
[24]
Xu Y, Zhou K, Yang Z, et al. Association of cytokine gene polymorphisms (IL6, IL12B, IL18) with Behcet’s disease: A meta-analysis. Z Rheumatol 2016; 75(9): 932-8.
[http://dx.doi.org/10.1007/s00393-015-0036-4] [PMID: 26800664]
[25]
Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet’s disease. Rheumatology (Oxford) 2003; 42(7): 860-4.
[http://dx.doi.org/10.1093/rheumatology/keg232R] [PMID: 12730545]
[26]
Boiardi L, Salvarni C, Casali B, et al. Single-nucleotide polymorphism located at position-607 of IL-18 gene promotor region in Behçet’s disease. Arthritis Rheum 2004; 9(Suppl.): S232.
[27]
Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behçet’s disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21(4)(Suppl. 30): S35-7.
[PMID: 14727457]
[28]
Bulur I, Onder M. Behçet disease: New aspects. Clin Dermatol 2017; 35(5): 421-34.
[http://dx.doi.org/10.1016/j.clindermatol.2017.06.004] [PMID: 28916023]
[29]
Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 1999; 341(17): 1284-91.
[http://dx.doi.org/10.1056/NEJM199910213411707] [PMID: 10528040]
[30]
Mumcu G, Inanc N, Yavuz S, Direskeneli H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet’s disease. Clin Exp Rheumatol 2007; 25(4)(Suppl. 45): S27-33.
[PMID: 17949548]
[31]
Cho SB, Zheng Z, Ahn KJ, et al. Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease. Br J Dermatol 2013; 168(5): 977-83.
[http://dx.doi.org/10.1111/bjd.12128] [PMID: 23137016]
[32]
Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet’s disease. Med Microbiol Immunol (Berl) 2003; 192(3): 149-55.
[http://dx.doi.org/10.1007/s00430-002-0167-5] [PMID: 12684757]
[33]
Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Behçet’s disease using a genome-wide association study. Arthritis Res Ther 2009; 11(3): R66.
[http://dx.doi.org/10.1186/ar2695] [PMID: 19442274]
[34]
Studd M, McCance DJ, Lehner T. Detection of HSV-1 DNA in patients with Behçet’s syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 1991; 34(1): 39-43.
[http://dx.doi.org/10.1099/00222615-34-1-39] [PMID: 1846653]
[35]
Demirkesen C, Tüzüner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol 2001; 116(3): 341-6.
[http://dx.doi.org/10.1309/GCTH-0060-55K8-XCTT] [PMID: 11554161]
[36]
Calgüneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet’s disease. A randomized clinical trial. Arthritis Rheum 1996; 39(12): 2062-5.
[http://dx.doi.org/10.1002/art.1780391216] [PMID: 8961912]
[37]
Calgüneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet’s disease. Dermatology (Basel) 1996; 192(2): 125-8.
[http://dx.doi.org/10.1159/000246336] [PMID: 8829493]
[38]
Yurdakul S, Yazici H. Behçet’s syndrome. Best Pract Res Clin Rheumatol 2008; 22(5): 793-809.
[http://dx.doi.org/10.1016/j.berh.2008.08.005] [PMID: 19028364]
[39]
Kiraz S, Ertenli I, Oztürk MA, Haznedaroğlu IC, Celik I, Calgüneri M. Pathological haemostasis and “prothrombotic state” in Behçet’s disease. Thromb Res 2002; 105(2): 125-33.
[http://dx.doi.org/10.1016/S0049-3848(02)00006-3] [PMID: 11958802]
[40]
Becatti M, Emmi G, Silvestri E, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in behçet disease. Circulation 2016; 133(3): 302-11.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017738] [PMID: 26585672]
[41]
Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol 2009; 5(6): 332-40.
[http://dx.doi.org/10.1038/nrrheum.2009.81] [PMID: 19434075]
[42]
Miniati M, Fiorillo C, Becatti M, et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181(9): 992-6.
[http://dx.doi.org/10.1164/rccm.200907-1135OC] [PMID: 20075386]
[43]
Becatti M, Marcucci R, Bruschi G, et al. Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction. Arterioscler Thromb Vasc Biol 2014; 34(7): 1355-61.
[http://dx.doi.org/10.1161/ATVBAHA.114.303785] [PMID: 24790138]
[44]
Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 1995; 18(4): 815-21.
[http://dx.doi.org/10.1016/0891-5849(95)93872-4] [PMID: 7750804]
[45]
Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76(4): 535-40.
[http://dx.doi.org/10.1055/s-0038-1650618] [PMID: 8902992]
[46]
Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63(1): 111-28.
[http://dx.doi.org/10.1016/S0006-3495(92)81594-1] [PMID: 1420861]
[47]
Lotti T, Matucci-Cerinic M. Cutaneous fibrinolytic potential, tPA dependent, is reduced in Behçet’s disease. Br J Dermatol 1989; 121(6): 713-6.
[http://dx.doi.org/10.1111/j.1365-2133.1989.tb08213.x] [PMID: 2514783]
[48]
Okada AA. Behçet’s disease: general concepts and recent advances. Curr Opin Ophthalmol 2006; 17(6): 551-6.
[http://dx.doi.org/10.1097/01.icu.0000247411.59213.bb] [PMID: 17065924]
[49]
Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014; 70(2): 291-6.
[http://dx.doi.org/10.1016/j.jaad.2013.09.013] [PMID: 24176522]
[50]
Capkin E, Karkucak M, Kola M, Karaca A, Aydin Capkin A, Caner Karahan S. Ischemia-modified albumin (IMA): a novel marker of vascular involvement in Behçet’s disease? Joint Bone Spine 2015; 82(1): 68-9.
[http://dx.doi.org/10.1016/j.jbspin.2014.06.007] [PMID: 25085590]
[51]
Korkmaz C, Bozan B, Kosar M, Sahin F, Gülbas Z. Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome? Clin Exp Rheumatol 2002; 20(4)(Suppl. 26): S30-4.
[PMID: 12371632]
[52]
Yazici H, Esen F. Mortality in Behçet’s syndrome. Clin Exp Rheumatol 2008; 26(5)(Suppl. 51): S138-40.
[PMID: 19026156]
[53]
Sari RA, Kiziltunc A, Taysy S, et al. Levels of soluble E-selectin in patients with active Behcet’s disease. Clin Rheumatol 2005; 24(1): 55-9.
[http://dx.doi.org/10.1007/s10067-004-0982-8]
[54]
Evereklioglu C, Inalöz HS, Kirtak N, et al. Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 2002; 147(2): 331-6.
[http://dx.doi.org/10.1046/j.1365-2133.2002.04703.x] [PMID: 12174107]
[55]
Kahraman T, Gucluler G, Simsek I, et al. Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet’s disease severity. J Extracell Vesicles 2017; 6(1)1284449
[http://dx.doi.org/10.1080/20013078.2017.1284449] [PMID: 28326169]
[56]
Bassyouni IH, Sharaf M, Wali IE, Mansour HM. Clinical significance of Angiopoietin-1 in Behcet’s disease patients with vascular involvement. Heart Vessels 2016; 31(6): 918-24.
[http://dx.doi.org/10.1007/s00380-015-0686-9] [PMID: 25964071]
[57]
Ling E, Shubinsky G, Press J. Increased proportion of CD3+CD4-CD8- double-negative T cells in peripheral blood of children with Behcet’s disease. Autoimmun Rev 2007; 6(4): 237-40.
[http://dx.doi.org/10.1016/j.autrev.2006.08.008] [PMID: 17317615]
[58]
Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci 2003; 60(9): 1903-22.
[http://dx.doi.org/10.1007/s00018-003-2333-3] [PMID: 14523551]
[59]
Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behçet’s disease. Clin Exp Rheumatol 2001; 19(5)(Suppl. 24): S19-24.
[PMID: 11760393]
[60]
Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol 1999; 73: 369-509.
[http://dx.doi.org/10.1016/S0065-2776(08)60791-9] [PMID: 10399011]
[61]
Yamashiro S, Kamohara H, Wang JM, Yang D, Gong WH, Yoshimura T. Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol 2001; 69(5): 698-704.
[PMID: 11358976]
[62]
Sakane T, Suzuki N, Takeno M. Innate and acquired immunity in Behc¸et’s disease. 8th International conference on Behçet’s disease. 56
[63]
Takeno M, Shimoyama Y, Suzuki N, Sakane T. Prolonged survival of auto-primed neutrophils from patients with Behçet’s disease. 8th International conference on Behçet’s disease. 57
[64]
Witowski J, Pawlaczyk K, Breborowicz A, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000; 165(10): 5814-21.
[http://dx.doi.org/10.4049/jimmunol.165.10.5814] [PMID: 11067941]
[65]
Niwa Y, Mizushima Y. Neutrophil-potentiating factors released from stimulated lymphocytes; special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of patients with Behçet’s disease. Clin Exp Immunol 1990; 79(3): 353-60.
[http://dx.doi.org/10.1111/j.1365-2249.1990.tb08095.x] [PMID: 2180598]
[66]
Leung BP, Culshaw S, Gracie JA, et al. A role for IL-18 in neutrophil activation. J Immunol 2001; 167(5): 2879-86.
[http://dx.doi.org/10.4049/jimmunol.167.5.2879] [PMID: 11509635]
[67]
Gunduz K, Ozturk G, Sozmen EY. Erythrocyte superoxide dismutase, catalase activities and plasma nitrite and nitrate levels in patients with Behçet disease and recurrent aphthous stomatitis. Clin Exp Dermatol 2004; 29(2): 176-9.
[http://dx.doi.org/10.1111/j.1365-2230.2004.01488.x] [PMID: 14987277]
[68]
Yazici C, Köse K, Caliş M, DemIr M, Kirnap M, Ateş F. Increased advanced oxidation protein products in Behçet’s disease: a new activity marker? Br J Dermatol 2004; 151(1): 105-11.
[http://dx.doi.org/10.1111/j.1365-2133.2004.06003.x] [PMID: 15270878]
[69]
Sancak B, Onder M, Oztas MO, Bukan N, Gürer MA. Nitric oxide levels in Behçet’s disease. J Eur Acad Dermatol Venereol 2003; 17(1): 7-9.
[http://dx.doi.org/10.1046/j.1468-3083.2003.t01-1-00574.x] [PMID: 12602959]
[70]
Kohn S, Haim S, Gilhar A, Friedman-Birnbaum R, Nir I. Epidermal Langerhans’ cells in Behçet’s disease. J Clin Pathol 1984; 37(6): 616-9.
[http://dx.doi.org/10.1136/jcp.37.6.616] [PMID: 6725610]
[71]
Kürkçüoğlu N, Çakar N. Epidermal Langerhans cells in patients with Behçet’s syndrome. Australas J Dermatol 1988; 29(3): 185-7.
[http://dx.doi.org/10.1111/j.1440-0960.1988.tb00398.x] [PMID: 3272129]
[72]
Saito T, Honma T, Saigo K. Epidermal Langerhans’ cells after the prick test for Behçet’s disease. Dermatologica 1980; 161(3): 152-6.
[http://dx.doi.org/10.1159/000250351] [PMID: 7398993]
[73]
Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20(9): 1544-9.
[PMID: 8164212]
[74]
Kötter I, Koch S, Vonthein R, et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005; 23(4)(Suppl. 38): S20-6.
[PMID: 16273760]
[75]
Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-36.
[http://dx.doi.org/10.1146/annurev.immunol.23.021704.115843] [PMID: 15771573]
[76]
Pay S, Simsek I, Erdem H, et al. Quantitative and functional analysis of dendritic cell subsets in Behçet’s disease: does functional abnormality in plasmacytoiddendtritic cell contribute to Th1 polarization? 12th International conference on Behçet’s disease. Lisbon. 2006.
[77]
Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behçet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998; 25(2): 329-33.
[PMID: 9489829]
[78]
Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum 2004; 50(7): 2291-5.
[http://dx.doi.org/10.1002/art.20334] [PMID: 15248229]
[79]
Hamzaoui A, Ghraïri H, Ammar J, Zekri S, Guemira F, Hamzaoui K. IL-18 mRNA expression and IFN-γ induction in bronchoalveolar lavage from Behçet’s disease. Clin Exp Rheumatol 2003; 21(4)(Suppl. 30): S8-S14.
[PMID: 14727452]
[80]
Cosan F, Aktas Cetin E, Akdeniz N, Emrence Z, Cefle A, Deniz G. Natural killer cell subsets and their functional activity in Behçet’s disease. Immunol Invest 2017; 46(4): 419-32.
[http://dx.doi.org/10.1080/08820139.2017.1288240] [PMID: 28388249]
[81]
Hasan MS, Ryan PL, Bergmeier LA, Fortune F. Circulating NK cells and their subsets in Behçet’s disease. Clin Exp Immunol 2017; 188(2): 311-22.
[http://dx.doi.org/10.1111/cei.12939] [PMID: 28170096]
[82]
Koarada S, Haruta Y, Tada Y, et al. Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet’s disease. Rheumatology (Oxford) 2004; 43(7): 843-51.
[http://dx.doi.org/10.1093/rheumatology/keh195] [PMID: 15150429]
[83]
Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31(4): 205-10.
[http://dx.doi.org/10.1080/030097402320318387] [PMID: 12369651]
[84]
de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behçet’s disease patients and controls. Invest Ophthalmol Vis Sci 2000; 41(11): 3480-4.
[PMID: 11006242]
[85]
Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006; 26(6): 545-50.
[http://dx.doi.org/10.1007/s00296-005-0029-8] [PMID: 16205927]
[86]
Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011; 128(3): 655-64.
[http://dx.doi.org/10.1016/j.jaci.2011.05.029] [PMID: 21724243]
[87]
Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49(7): 3058-64.
[http://dx.doi.org/10.1167/iovs.07-1390] [PMID: 18579762]
[88]
Kim ES, Kim SW, Moon CM, et al. Interactions between IL17A, IL23R and STAT4 polymorphisms confer susceptibility to intestinal Behcet’s disease in Korean population. Life Sci 2012; 90(19-20): 740-6.
[http://dx.doi.org/10.1016/j.lfs.2012.03.017] [PMID: 22483685]
[89]
Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products and cytokines. J Immunol 2002; 168(2): 554-61.
[http://dx.doi.org/10.4049/jimmunol.168.2.554] [PMID: 11777946]
[90]
Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet’s disease. Clin Exp Dermatol 2005; 30(1): 61-3.
[http://dx.doi.org/10.1111/j.1365-2230.2004.01684.x] [PMID: 15663506]
[91]
Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E. An elevated pro-inflammatory cytokines profile in Behcet’s disease: A multiplex analysis. Immunol Lett 2017; 186: 46-51.
[http://dx.doi.org/10.1016/j.imlet.2016.12.001] [PMID: 27939191]
[92]
Çerçi P, Altıner S, İnal A, Köse K, Keskin G, Ölmez Ü. Investigating the role of IL-33 in the pathogenesis of Behçet’s Disease. Acta Clin Belg 2017; 72(6): 434-8.
[http://dx.doi.org/10.1080/17843286.2017.1314241] [PMID: 28412856]
[93]
Ha YJ, Park JS, Kang MI, Lee SK, Park YB, Lee SW. Increased serum interleukin-32 levels in patients with Behçet’s disease. Int J Rheum Dis 2018; 21(12): 2167-74.
[PMID: 28378461]
[94]
Shimizu J, Takai K, Takada E, et al. Possible association of proinflammatory cytokines including IL1β and TNFα with enhanced Th17 cell differentiation in patients with Behcet’s disease. Clin Rheumatol 2016; 35(7): 1857-63.
[http://dx.doi.org/10.1007/s10067-015-2966-2] [PMID: 25972082]
[95]
Hamzaoui K. Th17 cells in Behçet’s disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011; 29(4)(Suppl. 67): S71-6.
[PMID: 21968241]
[96]
Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2017: Behçet's syndrome ClinExpRheumatol 2017; 108 |(6 ): 3-15.
[97]
Deniz R, Tulunay-Virlan A, Ture Ozdemir F, et al. Th17-Inducing Conditions Lead to in vitro Activation of Both Th17 and Th1 Responses in Behcet’s Disease. Immunol Invest 2017; 46(5): 518-25.
[http://dx.doi.org/10.1080/08820139.2017.1306865] [PMID: 28414558]
[98]
Direskeneli H. Behçet’s disease: infectious aetiology, new autoantigens and HLA-B51. Ann Rheum Dis 2001; 60(11): 996-1002.
[http://dx.doi.org/10.1136/ard.60.11.996] [PMID: 11602462]
[99]
Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. Cellular autoimmunity to retinal specific antigens in patients with Behçet’s disease. Br J Ophthalmol 1993; 77(9): 584-9.
[http://dx.doi.org/10.1136/bjo.77.9.584] [PMID: 8218058]
[100]
Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet’s disease. Cell Immunol 1992; 140(2): 410-9.
[http://dx.doi.org/10.1016/0008-8749(92)90207-6] [PMID: 1544169]
[101]
Hirohata S, Hashimoto T. Abnormal T cell responses to bacterial superantigens in Behçet’s disease (BD). Clin Exp Immunol 1998; 112(2): 317-24.
[http://dx.doi.org/10.1046/j.1365-2249.1998.00572.x] [PMID: 9649197]
[102]
Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Behçet’s disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 2003; 141(1): 33-40.
[http://dx.doi.org/10.1067/mlc.2003.1] [PMID: 12518166]
[103]
Ekşioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet’s disease: increased activity in B cell subsets. J Rheumatol 1999; 26(4): 826-32.
[PMID: 10229403]
[104]
Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118(3): 451-7.
[http://dx.doi.org/10.1046/j.1365-2249.1999.01069.x] [PMID: 10594567]
[105]
Monselise A, Weinberger A, Monselise Y, Fraser A, Sulkes J, Krause I. Anti-Saccharomyces cerevisiae antibodies in Behçet’s disease--a familial study. Clin Exp Rheumatol 2006; 24(5)(Suppl. 42): S87-90.
[PMID: 17067434]
[106]
Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behçet’s disease: a reassessment. Rheumatology (Oxford) 2001; 40(2): 192-5.
[http://dx.doi.org/10.1093/rheumatology/40.2.192] [PMID: 11257156]
[107]
Zeng XJ, Zhu WG, Deng XX, Tang FL, Dong Y. Anti-endothelial cell antibodies in systemic vasculitis: detection and correlation with disease activity. Zhonghua Yi Xue Za Zhi 2004; 84(19): 1629-32.
[PMID: 15569459]
[108]
Aslan H, Pay S, Gok F, et al. Antiannexin V autoantibody in thrombophilic Behçet’s disease. Rheumatol Int 2004; 24(2): 77-9.
[http://dx.doi.org/10.1007/s00296-002-0274-z] [PMID: 14658002]
[109]
Vural B, Demirkan A, Ugurel E, et al. Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with Behçet’s disease. Clin Exp Rheumatol 2009; 27(2)(Suppl. 53): S67-72.
[PMID: 19796537]
[110]
Tunc R, Ozbakir F, Caglayan A, et al. Absence of ANCA in Behçet syndrome with large vessel involvement. Angiology 2001; 10: 260-2.
[111]
Ergun T, Ince U, Ekşioğlu-Demiralp E, et al. HSP 60 expression in mucocutaneous lesions of Behçet’s disease. J Am Acad Dermatol 2001; 45(6): 904-9.
[http://dx.doi.org/10.1067/mjd.2001.117728] [PMID: 11712037]
[112]
Hasan A, Fortune F, Wilson A, et al. Role of gamma delta T cells in pathogenesis and diagnosis of Behcet’s disease. Lancet 1996; 347(9004): 789-94.
[http://dx.doi.org/10.1016/S0140-6736(96)90868-5] [PMID: 8622334]
[113]
Pervin K, Childerstone A, Shinnick T, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet’s disease. J Immunol 1993; 151(4): 2273-82.
[PMID: 7688396]
[114]
Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet’s disease. Clin Exp Rheumatol 2003; 21(4)(Suppl. 30): S44-8.
[PMID: 14727460]
[115]
Choi CH, Kim TI, Kim BC, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behçet’s disease patients: relation to clinical course. Dis Colon Rectum 2006; 49(12): 1849-59.
[http://dx.doi.org/10.1007/s10350-006-0706-z] [PMID: 17080284]
[116]
Filik L, Biyikoglu I. Differentiation of Behcet’s disease from inflammatory bowel diseases: anti-Saccharomyces cerevisiae antibody and anti-neutrophilic cytoplasmic antibody. World J Gastroenterol 2008; 14(47): 7271.
[http://dx.doi.org/10.3748/wjg.14.7271] [PMID: 19084948]
[117]
Direskeneli H, Keser G, D’Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet’s disease. Clin Rheumatol 1995; 14(1): 55-61.
[http://dx.doi.org/10.1007/BF02208085] [PMID: 7743745]
[118]
Aydìntug AO, Tokgöz G, D’Cruz DP, et al. Antibodies to endothelial cells in patients with Behçet’s disease. Clin Immunol Immunopathol 1993; 67(2): 157-62.
[http://dx.doi.org/10.1006/clin.1993.1059] [PMID: 8519091]
[119]
Lee KH, Chung HS, Kim HS, et al. Human α-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet’s disease. Arthritis Rheum 2003; 48(7): 2025-35.
[http://dx.doi.org/10.1002/art.11074] [PMID: 12847697]
[120]
Kang SE, Lee SJ, Lee JY, et al. Serum levels of IgG antibodies against alpha-enolase are increased in patients with Behçet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates and C-reactive protein. Clin Exp Rheumatol 2017; 35(6)(Suppl. 108): 67-74.
[PMID: 28770703 ]
[121]
van der Houwen TB, van Hagen PM, Timmermans WM, et al. Chronic signs of memory B cell activation in patients with Behçet’s disease are partially restored by anti-tumour necrosis factor treatment. Rheumatology (Oxford) 2017; 56(1): 134-44.
[http://dx.doi.org/10.1093/rheumatology/kew366] [PMID: 27744360 ]
[122]
Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features and management of mucocutaneous lesions. J Dermatol 2016; 43(6): 620-32.
[http://dx.doi.org/10.1111/1346-8138.13381] [PMID: 27075942]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Published on: 05 March, 2020
Page: [12 - 20]
Pages: 9
DOI: 10.2174/1573397115666190415142426
Price: $65

Article Metrics

PDF: 30
HTML: 4